logo
logo
QDEL stock ticker logo

QuidelOrtho Corporation

NASDAQ•QDEL
CEO: Mr. Joseph M. Busky CPA
セクター: Healthcare
業種: Medical - Instruments & Supplies
上場日: 1991-02-01
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
連絡先情報
9975 Summers Ridge Road, San Diego, CA, 92121, United States
858-552-1100
www.quidelortho.com
時価総額
$1.16B
PER (TTM)
-1.0
57.7
配当利回り
--
52週高値
$38.99
52週安値
$17.09
52週レンジ
0%
順位39Top 39.1%
4.2
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 4.2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$723.60M+0.00%
直近4四半期の推移

EPS

-$1.95+0.00%
直近4四半期の推移

フリーCF

$86.60M+0.00%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Total Revenues Decline Total revenues $2.73B USD, down 2% in 2025; prior year saw 7% revenue decrease compared to 2023.
Net Loss Significantly Improved Net loss $(1.13B) USD in 2025, significantly improving from $(2.05B) USD loss recorded in the prior year.
Major Goodwill Impairment Charges Recognized $700.7M goodwill impairment charge in 2025, following $1.8B USD impairment recorded during 2024.
Restructuring Charges Incurred $263.6M restructuring, integration, and other charges recorded in 2025; U.S. Donor Screening wind-down impacted revenue.

リスク要因

Intense Industry Competition Highly competitive industry nature risks losing market share or failing to meet customer expectations regarding product performance.
Supply Chain Disruptions Risk Interruptions and delays in raw material supply or manufacturing could adversely affect operations and financial performance.
Regulatory Compliance Exposure Failure to comply with complex FDA regulations or healthcare fraud/abuse laws risks penalties and operational restrictions.
High Indebtedness Level High indebtedness of $2.65B USD limits operational flexibility and increases vulnerability to variable interest rate fluctuations.

見通し

Optimization Plan Execution Focus Focus on executing multi-year Optimization Plan to realign costs and achieve $50M net cost savings through 2027.
Strategic Portfolio Refocusing Strategic refocusing includes discontinuing SAVANNA platform development and intent to acquire LEX Diagnostics in 2025.
Continued R&D Investment Continued investment in R&D for product expansion, new platform capabilities, and advanced digital integrations expected.
Sufficient Short-Term Liquidity Current cash $169.8M USD and RCF availability sufficient to fund near-term capital and operating needs for next 12 months.

同業比較

売上高 (TTM)

XRAY stock ticker logoXRAY
$3.68B
-3.0%
QDEL stock ticker logoQDEL
$2.73B
-1.9%
NHC stock ticker logoNHC
$1.52B
+16.8%

粗利益率 (最新四半期)

CLDX stock ticker logoCLDX
100.0%
+0.0pp
RCUS stock ticker logoRCUS
90.9%
-7.7pp
NVCR stock ticker logoNVCR
75.8%
-3.9pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
EWTX$3.17B-18.2-32.0%0.7%
TWST$2.65B-34.5-16.6%28.8%
NHC$2.51B20.811.6%5.7%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
1.5%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
50%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月5日
|
EPS:-
|
売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし